Rani Net Receivables from 2010 to 2024

RANI Stock  USD 1.99  0.04  2.05%   
Rani Therapeutics' Net Receivables is increasing with stable movements from year to year. Net Receivables is predicted to flatten to about 171 K. For the period between 2010 and 2024, Rani Therapeutics, Net Receivables quarterly trend regression had mean deviation of  185,147 and range of 1.5 M. View All Fundamentals
 
Net Receivables  
First Reported
2010-12-31
Previous Quarter
180 K
Current Value
171 K
Quarterly Volatility
385.2 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Rani Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Rani Therapeutics' main balance sheet or income statement drivers, such as Interest Income of 3.6 M, Depreciation And Amortization of 925.5 K or Interest Expense of 5.3 M, as well as many indicators such as Price To Sales Ratio of 130, Dividend Yield of 0.0 or PTB Ratio of 6.91. Rani financial statements analysis is a perfect complement when working with Rani Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Rani Therapeutics Correlation against competitors.

Latest Rani Therapeutics' Net Receivables Growth Pattern

Below is the plot of the Net Receivables of Rani Therapeutics Holdings over the last few years. It is Rani Therapeutics' Net Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Rani Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Net Receivables10 Years Trend
Pretty Stable
   Net Receivables   
       Timeline  

Rani Net Receivables Regression Statistics

Arithmetic Mean331,400
Geometric Mean263,239
Coefficient Of Variation116.24
Mean Deviation185,147
Median250,000
Standard Deviation385,232
Sample Variance148.4B
Range1.5M
R-Value0.12
Mean Square Error157.4B
R-Squared0.02
Significance0.66
Slope10,668
Total Sum of Squares2.1T

Rani Net Receivables History

2024171 K
2023180 K
2021200 K
20201.7 M

About Rani Therapeutics Financial Statements

Investors use fundamental indicators, such as Rani Therapeutics' Net Receivables, to determine how well the company is positioned to perform in the future. Although Rani Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Net Receivables180 K171 K

Currently Active Assets on Macroaxis

When determining whether Rani Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Rani Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Rani Therapeutics Holdings Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Rani Therapeutics Holdings Stock:
Check out the analysis of Rani Therapeutics Correlation against competitors.
You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Rani Therapeutics. If investors know Rani will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Rani Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.05)
Quarterly Revenue Growth
(1.00)
Return On Assets
(0.57)
Return On Equity
(2.25)
The market value of Rani Therapeutics is measured differently than its book value, which is the value of Rani that is recorded on the company's balance sheet. Investors also form their own opinion of Rani Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Rani Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Rani Therapeutics' market value can be influenced by many factors that don't directly affect Rani Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Rani Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Rani Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rani Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.